Laserfiche WebLink
7. HHS. The Business Associate agrees to make its internal practices, books and records <br />relating to the Use and Disclosure of PHI received from or created or received by the Business Associate <br />on behalf of the Company available to the Company and the Secretary of HHS for purposes of <br />determining the Company's compliance with the Regulations. Notwithstanding this Section 7, no <br />attorney-client privilege or other privilege shall be deemed waived by the Company or the Business <br />Associate. <br />8. Termination. Company and Business Associate shall each have the right to immediately <br />terminate this agreement upon the violation by the other of a material term of this Agreement or of the <br />Regulations, including violations relating specifically to the permitted and required Uses and Disclosures <br />of PHI by the Company or Business Associate; provided, however, that the breaching party shall be <br />provided the opportunity to cure the breach to the satisfaction of the other within a reasonable period of <br />time. If the beaching -party does not cure the default, the non -breaching party shall be entitled to terminate <br />this Agreement or if it is not feasible to terminate this Agreement, report the problem to the Secretary of <br />HHS. <br />Upon termination of this Agreement, the Business Associate and the Company agree to determine <br />whether the return or destruction of PHI received from, or created or received by the Business Associate <br />under this Agreement is feasible. If such return or destruction is mutually determined to be feasible, the <br />Business Associate shall promptly return or destroy all such PHI received from or created or received by <br />the Business Associate under this Agreement. If such return or destruction is mutually determined to not <br />be feasible, the protections of this Agreement shall continue to apply to such PHI after termination <br />(including the Business Associate's obligations in Section 5), and further Uses and Disclosures of such <br />PHI shall be restricted to only those purposes that make the return or destruction of the information <br />infeasible. If mutual agreement is not made as to the feasibility of any return or destruction of PHI, the <br />parties agree to use mediation to resolve this issue. <br />9. Term of A rueeement. The term of this Agreement shall be such period of time as the <br />Business Associate is performing the Services. In the event that such Services are terminated, this <br />Agreement also shall terminate, except that the provisions of Sections 8 and 15 shall survive any <br />termination of this Agreement. <br />10. Notice. All written communications, demands, and notices between the parties hereto <br />must be posted by first class mail, postage paid or express mail to the following addresses: <br />To the Business Associate: To the Company: <br />Lauren Simmons Attn: <br />RxBenefits, Inc, Indian River County Board of County Commissioners <br />P. O. Box 382377 1801 27th Street <br />Birmingham, Alabama 35238-2377 Vero Beach, FL 32960-3365 <br />11. Entire Agreement. This Agreement supersedes all previous contracts and constitutes the <br />entire agreement of whatever kind or nature existing between the parties with respect to the subject matter <br />hereof, and no party shall be entitled to benefits other than those specified herein. As between the parties, <br />no oral statement or prior written material not specifically incorporated herein shall be of any force and <br />effect; and the parties specifically acknowledge that in entering into and executing this Agreement, the <br />parties rely solely upon the representations and agreements contained in this Agreement and no others. <br />This Agreement may be amended only by an instrument in writing executed by the parties hereto and may <br />be supplemented only by documents delivered in accordance with the express terms hereof. <br />NOT FOR DISTRIBUTION. THE INFORMATION CONTAINED HEREIN IS CONFIDENTIAL, PROPRIETARY <br />AND CONSTITUTES TRADE SECRETS OF ESI AND RXBENEF ITS <br />35 <br />